NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 883.2 DKK | +0.07% |
|
-1.62% | +26.51% |
| 05-09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
| 05-09 | News Highlights : Top Company News of the Day - Thursday at 1 PM ET | DJ |
This Alphavalue article, the European leader in independent research, is only available to subscribers .Alphavalue is exclusively on MarketScreener. To unlock the article, SUBSCRIBE!
Already a customer? Log In
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.51% | 568B | |
| +32.36% | 698B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B | |
| -2.12% | 160B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk: Novo Nordisk on course to become Europe’s first trillion dollar company?
